Company Overview and News

Law of large numbers will aid flows into largecaps: Pioneer

2016-11-08 moneycontrol
In an interview with CNBC-TV18, Sandeep Shenoy, Pioneer Investcorp, says the large caps will be on the shopping list of most of the players.

FII flows lift Nifty to 52-wk high; Sensex soars 292 to top 28K

2016-07-25 moneycontrol
Banking, realty and oil & gas shares were among the star performers of the day, with the respective sectoral indices on the BSE gaining more than 1 percent each.

FII flows lift Nifty to 52-wk high; Sensex up 292 pts to top 28K

2016-07-25 moneycontrol
Banking, realty and oil & gas shares were among the star performers of the day, with the respective sectoral indices on the BSE gaining more than 1 percent each.

Mkt volatility may pave way for value buying: Pioneer Investcorp

2016-06-14 moneycontrol
Sandeep Shenoy of Pioneer Investcorp believes that the looming global risk events like the US Federal Reserve meeting and Brexit decision could lead to extreme volatility in market but investors could get some value buying opportunities.

FMCG, auto to gain from monsoon forecast, but hang on: Pioneer

2016-04-18 moneycontrol
Though the monsoon may not be as bad as last year, it will take at least three quarters for a good rainfall to actually translate into anything meaningful, says Sandeep S Shenoy,Strategist at Pioneer Investcorp.

Sensex erases early gains, Nifty hovers around 7850; Infosys up

2016-04-18 moneycontrol
Commodity currencies slumped while the safe-haven yen soared after global oil producers fail to agree on an output freeze, sending oil prices tumbling anew.

Related Articles

ACIA: Acacia Communications Analysis and Research Report

7m - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...